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Abstract
Background: The extracellular matrix is a dynamic and complex network of macromolecules responsible for maintaining
and influencing cellular functions of the airway. The role of fibronectin, an extracellular matrix protein, is well documented
in asthma. However, the expression and function of fibulin-1, a secreted glycoprotein which interacts with fibronectin, has
not been reported. Fibulin-1 is widely expressed in basement membranes in many organs including the lung. There are four
isoforms in humans (A–D) of which fibulin-1C and 1D predominate. The objective of this study was to study the expression
of fibulin-1 in volunteers with and without asthma, and to examine its function in vitro.
Methodology/Principal Findings: We used immunohistochemistry and dot-blots to examine fibulin-1 levels in bronchial
biopsies, bronchoalveolar lavage fluid and serum. Real-time PCR for fibulin-1C and 1D, and ELISA and western blotting for
fibulin-1 were used to study the levels in airway smooth muscle cells. The function of fibulin-1C was determined by
assessing its role, using an antisense oligonucleotide, in cell proliferation, migration and wound healing. A murine model of
airway hyperresponsiveness (AHR) was used to explore the biological significance of fibulin-1. Levels of fibulin-1 were
significantly increased in the serum and bronchoalveolar lavage fluid of 21 asthmatics compared with 11 healthy volunteers.
In addition fibulin-1 was increased in asthma derived airway smooth muscle cells and fibulin-1C contributed to the
enhanced proliferation and wound repair in these cells. These features were reversed when fibulin-1C was suppressed using
an antisense oligomer. In a mouse model of AHR, treatment with an AO inhibited the development of AHR to methacholine.
Conclusions: Our data collectively suggest fibulin-1C may be worthy of further investigation as a target for airway
remodeling in asthma.
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Introduction
Asthma is a chronic inflammatory disorder of the airways
characterized by variable and reversible airflow obstruction and
airway hyperresponsiveness (AHR). A key feature of asthmatic
airways is remodeling which involves thickening of the airway wall,
altered deposition of extracellular matrix (ECM) proteins [1,2] and
increased airway smooth muscle (ASM) mass. These structural
changes may result from an aberrant repair process in the lung,
which includes increased proliferation of the ASM cells [3,4].
Whilst current treatments control the symptoms of asthma, they
are unable to fully prevent or reverse airway remodeling.
The ECMmaintains airway function and structure by providing
mechanical support in addition to constituting a dynamic and
complex network that influences cellular function [5]. The ECM
deposited by asthma derived ASM cells is altered such that
increased amounts of collagen I and laminin [6,7,8], as well as
fibronectin (FN) are produced which mediate a range of cellular
interactions including migration, growth and differentiation.
Levels of the profibrotic cytokine transforming growth factor b
(TGFb) are elevated in the bronchoalveolar lavage (BAL) fluid in
asthma [9], and are increased in bronchial tissue [10]. TGFb
stimulated FN deposition is also enhanced in asthma derived
bronchial epithelium and fibroblasts [11,12].
Fibulin-1 (FBLN-1), a secreted glycoprotein, assists in stabilizing
the ECM. It associates with FN and a variety of other ECM
proteins including laminin and fibrinogen [13]. Mice deficient in
FN and FBLN-1 die perinatally due to abnormal lung develop-
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ment [14]. FBLN-1 expression has been reported in human lung
tissue using microarray technology, however, FBLN-1 was not
verified by PCR or at the protein level, nor were functional studies
carried out [15,16,17]. In addition, Laprise et al., reported reduced
FBLN-1D expression in asthma derived bronchial biopsies
compared with those derived from non-asthmatics [15]. However,
the function of FBLN-1 in the lungs and its role in asthma is
unknown.
Four isoforms of FBLN-1 have been identified to date in
humans, designated FBLN-1A, 1B, 1C, and 1D [18]. These
isoforms are splice variants which possess different C-terminal
sequences. Although a global increase of FBLN-1 is associated
with tumor cells [19], the FBLN-1 isoforms may have distinct,
important roles in regulating cellular behavior. Importantly, the
isoform FBLN-1C was not reported in previous studies that
examined human lung tissue. Recently, Hergeth et al., showed that
the proliferation of blood CD34+ progenitor cells is inhibited by
FBLN-1C [20]. We, and others, have shown that the proliferation
of ASM cells derived from asthmatic individuals is enhanced
compared with those from non-asthmatic individuals [4,21,22].
Given the contribution of the ASM cell to remodeling in asthma,
we hypothesized that FBLN-1C may play an important regulatory
role in the lung.
The aim of this study was to assess the production of FBLN-1C
by asthmatic and non-asthmatic volunteers, and further, to
determine its function in isolated cell systems, and in an in vivo
model of airway hyperresponsiveness.
Materials and Methods
Ethics Statement
The study was approved by the Ethics Review Committee of the
South West Sydney Area Health Service, Royal Prince Alfred
Hospital and The University of Sydney human research ethics
committee. All volunteers provided written informed consent.
Study population
Samples obtained from a total of 64 asthmatics and 63 non-
asthmatics were studied. Non-asthmatic ASM cells were obtained
from resected lung following thoracotomy or transplantation.
Bronchial biopsies, BAL fluid, serum and ASM cells were obtained
from volunteers with intermittent, mild persistent or moderate
persistent atopic asthma, according to GINA guidelines [23], or
healthy volunteers. Some samples were collected prior to and after
7 weeks of treatment with an inhaled corticosteroid (fluticasone
propionate (200 or 1000 mcg daily)). Healthy volunteers had no
history of asthma or other lung disease and normal spirometry.
Medication and smoking history was not available for all patients
in this study. The details of all the individuals from whom samples
were obtained are shown in Table S1.
Collection and preparation of samples
Bronchoalveolar lavage fluid and serum. BAL fluid was
obtained by means of flexible fibreoptic bronchoscopy from 20
asthmatics and 11 non-asthmatics. Specimens were collected via
normal saline lavage of the segmental airways and alveolar spaces
(BAL) and endobronchial biopsy of the mucosal lining of the
airway. To remove mucus and cells, the BAL fluid was filtered
through sterile gauze and centrifuged at 580 g for 5 min. The
acellular supernatant was stored at 280uC until used.
In addition, venous blood was collected from the forearm of
volunteers, 44 asthmatics and 15 non-asthmatics and was stored in
aliquots at 220uC until used.
Airway smooth muscle. ASM cells were isolated from 31
asthmatics and 44 non-asthmatics. ASM cells were isolated as
previously described [3]. Briefly, bronchial airways were dissected
from the surrounding parenchyma and blood vessels and cut
longitudinally. Subsequently, the airways were washed in ethanol
and sterile Hank’s balanced salt solution before dissection under a
dissecting microscope. Bronchial mucosa biopsies were placed in
Hank’s balanced salt solution (Invitrogen, Carlsbad, CA, USA) for
immediate dissection of the ASM bundles for culture. The
bronchial epithelial cell layer was removed with fine forceps
exposing the visible smooth muscle bundles which were then
dissected free from the surrounding tissue. The collected smooth
muscle bundles were, placed in Hank’s balanced salt solution and
centrifuged at 1506g for 10 min. Isolated pieces of muscle were
placed into 25 cm2 vented tissue culture flasks (BD Biosciences,
North Ryde, Australia) containing 2.5 mLs Dulbecco’s modified
eagle’s medium (DMEM) (Invitrogen) supplemented with 10%
fetal bovine serum (FBS) (JRH biosciences, Brooklyn, Australia)
and 2 U/mL penicillin, 2 mg/mL streptomycin, and 250 ng/mL
amphotericin B (2% antibiotics) (Invitrogen) and placed in a
humidified CO2 incubator (5% CO2 in air) and maintained at
37uC. Weekly, the medium was aspirated and replaced with
DMEM supplemented with 5% FBS, 1% GlutaMAXTM-I
supplement (Invitrogen) and 1% antibiotics (Growth medium).
Airway smooth muscle cell culture
ASM cells were seeded at a density of 16104 cells/cm2 with
growth medium for 9 d at 37uC/5% CO2. On day 5, the medium
was replenished with fresh growth medium. Cells were quiesced in
0.1% bovine serum albumin (BSA) (Sigma Aldrich, St Louis, MO,
USA), 1% GlutaMAXTM-I supplement, 1% antibiotics in DMEM
(quiescing medium) for 3 d and treated with either quiescing
medium or 10 ng/mL TGFb (R&D Systems, Minneapolis, MN,
USA) in quiescing medium for 8 (mRNA analysis) or 24 (protein
analysis) h.
Dot Blot
The levels of soluble FBLN-1 in serum, BAL fluid and ASM cell
supernatants were measured using dot blot techniques. The
protein levels of FBLN-1C were not measured as no isoform
specific antibody was available at the time of experimentation. As
a strong, specific signal for FBLN-1 was detectable in FBS this was
used as a positive control for these experiments. ASM cells were
cultured as described above in 96 well plates. After 24 h of
treatment, supernatants were removed and stored at 220uC until
analyzed.
Polyvinylidene fluoride (PVDF) membrane (Immobilon–P,
0.45 mm pore size) (Millipore, Billerica, MA, USA) was cut and
pre-wet with 100% methanol for 10 min and then titrated into
phosphate buffered saline (PBS) for 15 min before being placed in
the blot apparatus. Human serum (50 mL, diluted 1:1000 in PBS),
BAL fluid (no dilution), supernatant (no dilution), FBS (diluted 1:2
in PBS) (positive control) or PBS (negative control) were loaded
into separate slots. A vacuum was applied until the samples were
evacuated. The membrane was washed 3 times with PBS and the
flow through removed with the aid of the vacuum.
The membrane was blocked in 5% (w/v) BSA/PBS-Tw
(blocking buffer) for 1 h at room temperature. Primary antibody,
monoclonal mouse anti-human FBLN-1 antibody (1 mg/mL in
1% (w/v) BSA in PBS-Tw) (Alexis Biochemicals, San Diego, CA,
USA), was added and incubated for 1 h at room temperature. The
membrane was then washed 3 times with PBS-Tw and a
biotinylated goat anti-mouse secondary antibody (1:20 000
dilution in 1% (w/v) BSA/PBS-Tw) (Millipore) added, and
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incubated for 1 h at room temperature. After washing 3 times with
PBS-Tw, streptavidin horseradish peroxidise (HRP) (0.5 mg/mL in
1% (w/v) BSA/PBS-Tw) (R&D Systems) was added for 1 h at
room temperature. The membrane was washed with PBS-Tw for
15 min and chemiluminescence (West Dura Extended duration
substrate kit, Pierce, Rockford, IL, USA) was visualized. The
image was captured and densitometric data were obtained using
Kodak MI software (version 4.0.5) (Kodak Scientific Imaging
Systems, Rochester, NY, USA). We normalized the values for
FBLN-1 by first subtracting the background and then expressing it
as a fold change from the positive control, 50% (v/v) FBS.
Fibulin-1C downregulation by transcript specific targeted
antisense oligmer
ASM cells were seeded at a density of 16104 cells/cm2 in growth
medium for 1 d at 37uC/5% CO2. A FBLN-1C antisense oligomer
(AO) consisting of 29-0-methyl modified bases on a phosphorothio-
ate backbone (59 CUUGCUAAGACUUUAUUAACGCC) was
used to downregulate FBLN-1C mRNA and protein, and a
scrambled AO (59 AUUUUGUCUGAAACCCUGUAAAGAG)
was used as the negative control. We recognized the high homology
between the different FLBN-1 isoforms and therefore we targeted
the transcript specific final exon of FBLN-1C. The AO directed
against FBLN-1C targeted the 1C polyadenylation site in the
39UTR and was specific for that transcript only. If aligned with the
FBLN-1D polyadenylation site, the FBLN-1C 23mer contains 15
mis-matches to the 1D sequence, precluding any potential cross
annealing. We have previously shown that a highly effective AO
loses all activity with 3 consecutive mismatches [24].
For 6 well plates (1.6 mLs of medium), 200 nM of either the
scrambled AO or FBLN-1C AO, 19.012 mg of enhancer buffer
and 3.34 mg of EffecteneH transfection reagent was added to
transfect the cells according to the manufacturer’s instructions for
72 h (EffecteneH transfection reagent, Qiagen, Doncaster, Aus-
tralia). For different sized plates, the concentration of the
transfection reagent was adjusted. Cells were quiesced in quiescing
medium for a further 3 d.
To produce ECM with suppressed FBLN-1C expression, ASM
cells were seeded in 75 cm2 flasks and transfected as described
above. ASM cells were reseeded into 24 or 96 well plates
maintaining the presence or absence of transfection reagent for a
further 3 d. ASM cells were lyzed using 0.016 mM sterile NH4OH
at 37uC for 20 min as previously described [25,26]. The wells were
washed five times with sterile PBS and stored in sterile PBS at
220uC.
Real Time PCR
ASM cells were seeded in 6 well plates as described above. After
8 h of treatment with or without 10 ng/mL TGFb, total cellular
RNA was extracted using the NucleoSpin RNA II kit according to
the manufacturer’s instructions (Macherey-Nagel GmbH & Co,
Duren, Germany). RNA was eluted in 50 mL of RNase free water
compared with 60 mL as specified by the manufacturer.
Reverse transcription of total RNA and real time PCR was
performed as described previously [27]. Predeveloped assay on
demand primers were used as follows FBLN-1: Hs00242545_m1;
FBLN-1C: Hs00242546_m1; FBLN-1D Hs00197774_m1 (Ap-
plied Biosystems, Foster City, CA, USA). The data were expressed
as a fold change relative to the non-stimulated (0.1% BSA) sample.
Western blotting
ASM cells were seeded in 6 well plates as described above. After
24 h of treatment with or without 10 ng/mL TGFb, cells were
lyzed using 50 mL of protein lysis buffer (0.9% (w/v) NaCl, 20 mM
Tris HCl (pH 7.6), 0.1% (v/v) Triton X-100, 1mM phenylmetha-
nesulphonylfluoride (PMSF) and 1% (v/v) protease inhibitor
cocktail (Calbiochem, Gibbstown, NJ, USA)) and stored at
220uC until required.
Western blotting was carried out as described previously [28]
with the following modifications. We mixed and denatured 30 mL
of protein with 6 mL of loading buffer (2% sodium dodecyl
sulphate (SDS), 7.5% glycerol, 31.25 mM Tris-HCl (pH 6.8),
0.0025% bromophenol blue, 200 mM DTT) at 95uC for 5 min.
As a positive control, 25 mg of SK-BR-3, a human breast
carcinoma cell line known to express FBLN-1 (Abgent, San
Diego, CA, USA) was used. The PVDF membrane was blocked
with blocking buffer (5% (w/v) BSA in 0.05% (v/v) Tween-20 in
PBS) followed by the addition of antibodies diluted in 1% BSA/
PBS-Tw. Antibodies used to analyze FBLN-1 levels were a
monoclonal mouse anti-human FBLN-1 antibody (1 mg/mL)
followed by a biotinylated secondary goat anti-mouse antibody
(1 in 20 000 dilution) and streptavidin HRP (0.5 mg/mL) each
Figure 1. FBLN-1 is increased in the serum and BAL of
asthmatics. FBLN-1 levels in serum (A) or BAL fluid (B) from non-
asthmatic (white) (n = 11) or asthmatic (black, pre and post corticoste-
roid treatment, n = 20) volunteers. Densitometric values are expressed
relative to the positive control FBS. Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g001
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incubated for 1 h at room temperature. To analyze glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), a housekeeping
monoclonal mouse anti-human GAPDH antibody (0.002 ng/
mL) (Santa Cruz Biotechnology) was incubated for 2 h followed by
a goat anti-mouse secondary antibody (0.4 mg/mL) (Santa Cruz
Biotechnology) for another h.
The values for FBLN-1 were normalized against those obtained
for GAPDH on the same membrane and are expressed as a fold
change relative to non-stimulated cells (0.1% BSA). To enable the
comparison of the basal level of FBLN-1, the levels of FBLN-1
were normalized against the positive control, whole cell lysates of
the SK-BR-3 human breast carcinoma cell line.
ECM Enzyme Linked Immunosorbent Assay
ASM cells were seeded in 96 well plates and grown in 100 mL of
growth medium as described above and treated with or without
10 ng/mL TGFb for 24 h. ASM cells were lyzed using 0.016 mM
NH4OH at 37uC for 20 minutes. The wells were washed five times
with PBS and stored with 50 mL/well of PBS at 220uC until
analyzed.
The deposition of FBLN-1 in the ECM was assessed using an
ECM ELISA according to methods described previously [29]. On
the day of the ELISA, after defrosting and another wash, a seven
point standard curve, ranging from 0.3125% to 20% (v/v) FBS in
PBS, was loaded on to each plate. All antibodies were added at
50 mL/well and diluted in 1% BSA/PBS-Tw. Monoclonal mouse
anti-human FBLN-1 antibody (2 mg/mL) was used as the primary
antibody, and the isotype control was a mouse IgM (2 mg/mL).
For measurement of FBLN-1 or its isotype control, a biotinylated
sheep anti-mouse antibody (5 mg/mL) (Millipore) was then added
followed by steptavidin HRP (0.5 mg/mL). ECM was quantified
by reading the plate at 405 nm using a Wallac-Victor 2 plate
reader and software (Perkin Elmer Life Sciences, Rowville,
Australia).
The data are expressed as fold change relative to non-stimulated
cells (0.1% BSA). In addition, the deposition of FBLN-1 in the
ECM was compared with standard curves. Samples and standard
curves were analyzed using Microplate Manager (Version 4.0, Bio-
Rad Laboratories, Hurcules, CA). FBLN-1 is expressed as a
percentage of the FBS standard.
Detection of fibulin-1 and fibronectin in airway smooth
muscle cells
ASM cells were seeded in eight well glass chamber slides (Nalge
Nunc, Rochester, NY, USA) and cultured as described above.
Figure 2. TGFb induced FBLN-1C mRNA in asthmatic ASM cells. Basal expression of FBLN-1C (A) and FBLN-1D (B) mRNA (expressed as cycle
threshold difference between FBLN-1C or D and 18s rRNA) from ASM cells collected from non-asthmatic (white bars n = 12) or asthmatic (black bars,
n = 8) volunteers, or expression following treatment for 8 h with TGFb of FBLN-1C (C) and FBLN-1D (D) (data were normalized to 18s rRNA and are
expressed relative to BSA at 8 h). Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g002
Figure 3. TGFb induced FBLN-1 protein in asthmatic ASM cells.
FBLN-1 protein was detected by western blot following TGFb
stimulation for 24 h of ASM cells collected from non-asthmatic (white
bars, n = 4) or asthmatic (black bars, n = 4) volunteers. Data were
normalized to the house keeping protein GAPDH and are expressed
relative to a positive control of the cell line SKBR3. Data are expressed as
mean 6 SEM.
doi:10.1371/journal.pone.0013360.g003
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After 24 h of treatment, the cells were fixed using cold 4%
paraformaldehyde for 20 min at 4uC.
The slides were blocked in 1% (w/v) BSA in PBS for 30 min at
room temperature and washed in PBS three times. A polyclonal
rabbit anti-human FBLN-1 antibody (4 mg/mL in PBS) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and a polyclonal
rabbit anti-human FN antibody (3 mg/mL in PBS) (Sigma Aldrich,
St Louis, MO, USA) were conjugated with Alexa Fluor 555
(12 mg/mL in PBS) and Alexa Fluor 647 (1 mg/mL in PBS),
respectively, in 10 mL PBS using a Zenon Rabbit IgG Labeling Kit
(Molecular Probes, Heidelberg, Australia). After 5 min incubation
in the dark, a non-specific rabbit IgG (Alexa Fluor 555: 300 mg/
mL and Alexa Fluor 647: 25 mg/mL, both in PBS) was added to
each sample and incubated in the dark for a further 5 min. The
two antibody samples were combined in PBS (antibody:zenon
complex). One hundred mL of the antibody:zenon complex was
added to each well of the chamber slide and incubated for 1.5 h at
room temperature in the dark. After incubation, slides were
washed in PBS three times and refixed in cold 4% paraformal-
dehyde for 20 min at 4uC. Slides were washed in PBS three times
prior to being coverslipped using 15% (v/v) glycerol in PBS,
pH 8.0. The cells were visualized using filters 575–615 and
650 nm for Alexa 555 and 647, respectively, using a Zeiss EC
Plan-Neofluar 4060.75 NA dry objective on a laser scanning
confocal microscope (Zeiss LSM 510 Meta Axioplan 2).
Wound healing
Airway smooth muscle cells. ASM cells were seeded in 24
well plates in the presence or absence of the FBLN-1C AO. A
scrambled AO and EffecteneH alone were used as negative
controls. A wound, approximately 1 cm in length was made in the
cell monolayer with a yellow pipette tip (P200, QSP, Pathtech,
Preston, Australia). The wells were washed twice with sterile PBS
and replenished with either quiescing medium or 10 ng/mL
TGFb in quiescing medium for up to 72 h.
Airway smooth muscle cells on a non-autologous
extracellular matrix. ECM in which FBLN-1C was suppressed
was produced using the FBLN-1C AO and prepared as described
above. ASM cells were then reseeded on top of this non-autologous
matrix as previously described [6]. A wound was made in the cell
monolayer as described for ASM cells.
Wound healing assay. The wound was observed using phase
contrast microscopy with an Olympus microscope (model CK2)
and images of the entire wound were taken at 0, 16, 24, 48 and
72 h post wound induction with an Olympus digital camera
(model C-4000).
Images of each wound were merged into a single image, such
that the image contained the whole wound using Adobe Photo-
shop CS3 (Adobe Systems). The area of each wound at each
different time point was measured in pixels, using ImageJ 1.37v
software. The percentage of wound closure compared with the
initial wound size was calculated using the equation.
% wound closure compared with 0 hr
~100{100|
Wound area tx
Wound area t0
 
Where tx is the wound area at a given time point and t0 is the initial
wound area
Cell proliferation
Cell proliferation was assessed by MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium] (Sigma Aldrich, St Louis, MO,
USA) assay as previously described [30]. FBLN-1C expression in
the ECM was suppressed by AO treatment and ASM cells were
reseeded on the ECM as previously described [6]. ASM cell
proliferation was measured after 72 h, with the addition of
0.5 mg/mL of MTT 5 h before the experimental end point.
Absorbance was measured at test wavelength 570 nm and
reference wavelength 655 nm.
Cell migration
ASM cell migration was examined using a modified Boyden
chamber protocol. To prepare ECM ASM cells were cultured and
transfected with and without FBLN-1C AO, in cell culture inserts
(uncoated, 8.0 mm pore size, transparent polyethylene terephthal-
ate membrane, BD Biosciences). After 4 days of growth the cell
culture inserts were washed once and then frozen at 220uC in
sterile PBS to lyze the cells and expose the ECM. The inserts were
stored at 220uC prior to use. ASM cells were seeded in 75 cm2
flasks at a density of 16104 cells/cm2 in growth medium at 37uC/
5% CO2. After 4 d of growth, ASM cells were quiesced in
quiescing medium for 3 d. Twenty h prior to the assay, cells were
Figure 4. TGFb induced FBLN-1 in ECM produced by asthmatic
ASM cells. Basal expression of FBLN-1 (A) deposited by ASM cells
collected from non-asthmatic (white bars, n = 10) or asthmatic (black
bars, n = 10) volunteers, or FBLN-1 levels following treatment for 24 h
with TGFb (B). Data were normalized to a positive control (50% FBS) and
are expressed relative to 0.1% BSA (non-stimulated). Data are expressed
as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g004
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treated with either quiescing medium or 10 ng/mL TGFb in
quiescing medium.
Cell culture inserts with a pre-laid ECM generated from ASM
cells were defrosted and washed an additional four times in sterile
PBS to remove cell debris, and once in DMEM. ASM cells from
the 75 cm2 flasks were trypsinized, centrifuged, and washed in
5 mL sterile PBS twice. After the final centrifugation, the cells
were resuspended in quiescing medium maintaining the absence
or presence of 10 ng/mL TGFb. The cells were seeded into the
inner chamber of the cell culture inserts as per the manufacturer’s
instructions (BD Biosciences). Growth medium was used as a
chemoattractant. In addition to the specified controls, a no cell
control for each matrix type was also used which consisted of
quiescing medium added to the exposed ECM in the inner
chamber and growth medium to the outer chamber.
ASM cells were allowed to migrate for 4 h at 37uC/5% CO2
then labeled and dissociated with a cell dissociation/Calcein-AM
solution (16 cell dissociation solution (Bio Scientific Pty Ltd,
Gymea, Australia), 2.4 mg Calcein AM (Molecular Probes) diluted
in sterile water) according to the manufacturer’s instructions. The
cells were labeled for a total of 1.25 h before quantification using
fluorescence (485 nm excitation and 520 nm emission on the
SpectraMax M2 plate reader (Molecular Devices, Camberwell,
Australia).
The fluorescence value of the ‘no cell control’ was subtracted
from corresponding samples of the same matrix type. Data are
expressed as fold change relative to ‘no chemoattractant’ sample.
Generation, treatment and assessment of a mouse model
of airway hyperresponsiveness
Adult BALB/c mice (6 to 8 weeks old) were administrated
200 ng of recombinant human TGFb (R&D Systems, Minneapo-
lis, MN, USA) intratracheally on days 0 and 1 to induce AHR.
Briefly, prior to anesthesia, the mice were warmed using a heat
lamp. Mice were anesthetized by IV injection with 12.5 mg/kg
Alfaxalone (Jurox, NSW, Australia) before being suspended
vertically and orotracheally intubated with a 22-gauge flexible
plastic catheter (Terumo Sureflo, Hospital Supplies of Australia).
Endotracheal positioning was confirmed by palpation of the
tracheal rings with the catheter tip. Mice were administered 40 mL
of PBS with or without 200 ng TGFb. Animals remained vertical
for 1 to 2 min after administration to ensure the inoculums
remained in the lungs.
A series of AOs targeting FBLN-1 (59 CACUUGGCGCAC-
GACACCUGGGGA; 59 UGAACUUGAUCCACUCACCCU-
CAGG; and 59 UUUUCUCUUGGCGGAAGCUGCAGA) were
used in equal parts to silence the expression of FBLN-1 in the
mice, and a scrambled AO (59 AUUUUGUCUGAAACCCU-
GUAAAGAA) was used as a negative control. The mice were
anesthetized with isofluorane (4%) and treated with 40 mL of PBS
alone, or containing 40 mg of FBLN-1 specific or scrambled AO
intranasally. Treatment occurred daily for the first 7 days, and
then 3 times weekly for the following three weeks.
AHR was assessed, in vivo, by measuring changes in transpul-
monary resistance and dynamic compliance using a Buxco (Buxco,
Figure 5. Wound healing is enhanced in asthmatic ASM cells. The degree of closure, measured over time, of a 1cm wound induced in non-
asthmatic (white, n = 3–4) or asthmatic (black, n = 3–4) unstimulated (A) or TGFb stimulated (B) ASM cells. The cells were reseeded on an ECM
deposited by an asthmatic ASM cell line in the absence (C) or presence (D) of TGFb. Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g005
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Willmington, NC, USA) invasive mouse plethysmograph on day
29 [31]. Mice were anesthetized with an intraperitoneal injection
of ketamine/xylazine (80–100 mg/kg and 10 mg/kg respectively)
and cannulated via the trachea with an 18 gauge metal cannula.
Mice were then mechanically ventilated (150 strokes/min, 175 mL
stroke volume). Volume changes due to thoracic expansion with
ventilation were measured by a transducer connected to the
plethysmograph flow chamber. Once stabilized, the mice were
challenged with 10 mL of saline, followed by increasing concen-
trations of methacholine (0.625, 1.25, 2.5, 5, 10 and 20 mg/mL),
aerosolized by an ultrasonic nebuliser and administered directly to
the lungs via the inspiratory line. Each aerosol was delivered for a
period of 5 min, during which pressure and flow data were
continuously recorded. A BioSystemXA (Buxco Electronics,
Willmington, NC, USA) was used to calculate pulmonary
resistance and compliance. Peak values were taken as the
maximum response to the concentration of methacholine being
tested. Data are expressed as the percentage change over the PBS
control.
Statistics
For seeding experiments, in which the characteristics of the
ASM cells were being investigated, all data collected from ASM
cells derived from a single volunteer seeded on different ECMs
were averaged. Likewise, where the characteristics of the ECM
were investigated, all results obtained when assorted ASM cells
were seeded on matrices deposited by ASM derived from a single
volunteer were averaged.
Gaussian distribution was determined by the Kolmogorov-
Sminov test, where an alpha level greater than 0.05 was considered
the threshold. For experiments that compared cells or ECM derived
from different volunteers, analysis was conducted using an unpaired
t-test. For experiments comparing more than two factors within
each disease group, analysis was conducted using one-way ANOVA
(Bonferroni post test). For experiments comparing two or more
factors and between disease groups, analysis was performed using
two-way ANOVA (Bonferroni post test). A p value of less than 0.05
(p#0.05) was considered statistically significant.
Data were analyzed using GraphPad Prism version 5.00
(GraphPad Software, San Diego, CA, USA).
Results
Fibulin-1 levels are increased in serum and BAL fluid from
asthmatic volunteers
We measured FBLN-1 levels in serum (figure 1A) and BAL fluid
(figure 1B) from 20–44 asthmatic and 11–15 non-asthmatic
volunteers by dot blot analysis. FBLN-1 levels were greater in
volunteers with asthma compared with those without asthma and
these levels were not altered by in vivo corticosteroid treatment
(figure 1A & B). There was no correlation between the FBLN-1
level detected in the serum or BAL from the asthmatic volunteers
and their FEV1/FVC ratio (data not shown).
Figure 6. Efficiency and specificity of FBLN-1C AO. Inhibition of
FBLN-1C (A) or FBLN-1D (B) mRNA following transfection with the FBLN-
1C AO or a scrambled AO in ASM cells collected from non-asthmatic
(white bars, n = 4) or asthmatic (black bars, n = 4) volunteers basally or
following treatment for 8 h with TGFb (data were normalized to 18s
rRNA and are expressed relative to the transfection control at 8 h).
FBLN-1 cellular and ECM deposited protein from ASM cells inhibited by
a FBLN-1C specific AO (C). Data were normalized to a positive control
(50% FBS) and are expressed relative to the transfection control. Data
are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g006
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TGFb upregulates fibulin-1C mRNA and FBLN-1 protein
levels in ASM cells derived from people with asthma
There were no differences in the basal expression of FBLN-1C
or 1D mRNA between asthmatic and non-asthmatic ASM cells
(figure 2A & B). TGFb induced FBLN-1C mRNA in the ASM
cells derived from asthmatic volunteers (P,0.001) but did not
increase the level of FBLN-1D mRNA, rather it decreased it
(p,0.001, figure 2 C & D). Neither FBLN-1C nor 1D expression
was altered by TGFb in the non-asthmatic cells. FBLN-1 protein
was induced by TGFb stimulation of ASM cells from asthmatic
but not non-asthmatic volunteers as assessed by western blotting
(figure 3). It was not possible to determine if this was due to an
increase in FBLN-1C protein as a commercial antibody, which
could distinguish between the FBLN-1 isoforms, was not available
at the time of this study. We also analyzed ECM FBLN-1
deposition from ASM cells by ELISA. Levels of FBLN-1 in the
ECM were the same in unstimulated non-asthmatic and asthmatic
ECM (figure 4A). However, TGFb increased FBLN-1 deposition
in the ECM from asthmatic ASM cells (P,0.01, figure 4B). In
addition to measuring FBLN-1 deposited in the ECM we also
measured it in cell culture supernatants (soluble FBLN-1). ASM
cell derived soluble FBLN-1 levels from the two patient groups
were not different, either basally or after stimulation with TGFb
(data not shown).
Rate of wound repair is increased in Asthmatic ASM cells
In a standard wound healing assay [32], 24 h post wound
induction, the rate of wound closure was significantly greater in
asthma derived ASM (12.463.4%) when compared with non-
asthma derived ASM (4.261.2%, (P,0.05). The increased rate of
wound closure by asthmatic ASM cells was maintained in the
presence of BSA up to 72 h (figure 5A). TGFb stimulation
enhanced the ability of the ASM cells to close a wound made in
the cell layer but this was still greater in the asthmatic ASM cells
than the non-asthmatic cells (figure 5B). The enhanced capacity of
the asthmatic cells was, in part, driven by the ECM deposited by
the cells, as reseeding non-asthmatic cells on a matrix deposited by
asthmatic cells increased the capacity of the non-asthmatic cells to
close the wound (figure 5C & D).
Functional role of fibulin-1
To delineate the role of FBLN-1C in regulating the behavior of
ASM cells we silenced its expression using a specific AO.
Transfection of the FBLN-1C specific AO decreased FBLN-1C
mRNA expression in asthmatic and non-asthmatic ASM derived
cells compared with the transfection control (EffecteneH) (P,0.05,
P,0.01 respectively, figure 6A) whilst there were no changes in
the mRNA levels of FBLN-1D (figure 6B). The scrambled AO had
no effect on FBLN-1C or FBLN-1D mRNA expression. The two
fold increase in FBLN-1 protein induced by TGFb, detected using
Figure 7. FBLN-1C AO does not alter FN deposition in ECM.
Inhibition of ECM deposited FBLN-1 (A) or FN (B) following transfection
with a FBLN-1C AO or a scrambled AO in ASM cells from asthmatic
volunteers (n = 4) basally or following treatment with TGFb for 24 h.
Data are expressed as mean 6 SEM. Concentrations were obtained by
interpolation of standard curves.
doi:10.1371/journal.pone.0013360.g007
Table 1. mRNA expression of fibronectin in FBLN-1 AO
transfected asthmatic ASM cells in the presence of TGFb
measured by quantitative real time PCR.
TRANSFECTION ASTHMATIC ASM CELLS
EffecteneH 1.28 (60.08) [P,0.05]
Scrambled AO 1.50 (60.17) [P,0.05]
FBLN-1C specific AO 1.57 (60.21) [P,0.05]
Cells were derived from asthmatic (n = 6) volunteers and treated with
EffecteneH only, or transfected with 200 nM scrambled AO or FBLN-1C specific
AO for 72 h. Cells were treated with either 0.1% BSA or 10 ng/mL TGFb for 8 h.
Expression levels were normalised to the housekeeping gene 18S. Data are
expressed as fold change compared with 0.1% BSA values and shown as mean
6 SEM [P value]. P values compared with their respective non-stimulated (0.1%
BSA) values.
doi:10.1371/journal.pone.0013360.t001
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western blot, was maintained in the presence of the transfection
control (EffecteneH) and the scrambled AO. However the FBLN-
1C AO almost completely abolished the TGFb induced increase
in protein (figure 6C). This did not occur when the ECM was
derived from non-asthmatic cells. The increased FBLN-1 in the
presence of TGFb, detected in the ECM deposited by asthmatic
ASM cells, was inhibited by the FBLN-1C specific AO (figure 7A).
Fibronectin mRNA (table 1) and protein levels (figures 7B & 8)
were increased in the presence of TGFb in the asthmatic ASM
cells but were unchanged by the FBLN-1C AO. We did not
examine the FN levels in non-asthmatic ASM cells as we had not
seen an induction of FBLN-1 in these cells.
Fibulin-1 is involved in wound repair in asthma derived
ASM cells. The FBLN-1C AO decreased the enhanced wound
closure of asthmatic ASM cells both in the presence and absence of
TGFb (figure 9A & B). However this only occurred in the presence
of TGFb in non-asthma derived ASM cells (figure 9A & B).
Transfection with a scrambled AO did not affect wound closure
(data not shown).
Fibulin-1 is involved in cell proliferation in asthma
derived ASM cells. Consistent with previous reports [3,4], we
confirmed that proliferation was increased in asthma derived ASM
cells (data not shown) and also when asthmatic ASM cells
(compared with non-asthmatic cells) were seeded on an asthma
derived ECM [6]. Importantly, proliferation of asthmatic ASM
cells was decreased when the cells were seeded onto an ECM
produced by FBLN-1C AO treated cells (figure 10). Proliferation
of non-asthmatic ASM cells was also suppressed when the cells
were reseeded on a matrix produced by asthmatic ASM cells
transfected with the FBLN-1C AO (figure 10). Transfection with
the scrambled AO did not alter ASM cell proliferation (data not
shown).
Fibulin-1 is not involved in migration of asthma derived
ASM. Basal cell migration was increased in the asthmatic ASM
cells when seeded on an asthma derived ECM (P,0.05)
(figure 11A). However in the presence of a chemoattractant (5%
FBS) chemotaxis of both non-asthmatic and asthmatic ASM cells
occurred (P,0.01; P,0.001 respectively, Figure 11B). When
FBLN-1C was silenced by the AO in the asthma derived ECM,
migration of either cell type was not altered (figure 11C).
Fibulin-1 contributes to the development of airway
hyperresponsiveness in a murine model
In a murine model of airway hyperresponsiveness TGFb
increased the resistance (Figure 12) and decreased the compliance
(data not shown) to methacholine in comparison with saline
treated animals, demonstrating that AHR was induced (P,0.001,
P,0.05 respectively). AHR induced by TGFb was abolished (to
similar levels to those seen in saline treated controls) when the
mice were treated with the FBLN-1 AO. In the presence of TGFb
and the FBLN-1 AO resistance and compliance were not different
from those in saline (Figure 12) or saline/FBLN-1 AO (data not
shown) treated animals. Further, the scrambled AO did not alter
airway resistance or compliance (P.0.05) in the presence or
absence of TGFb (data not shown).
Discussion
In the present study, we demonstrated for the first time that the
expression of FBLN-1 is increased in asthma. In-vivo, FBLN-1 levels
were increased in BAL fluid and serum from asthmatic volunteers.
In-vitro, TGFb increased the expression of FBLN-1 in ASM cells.
The increased FBLN-1 resulted in exaggerated proliferation and
wound repair in asthma derived ASM cells which was reduced
when only the FBLN-1C isoform was downregulated.
The current study demonstrates that FBLN-1 is differentially
expressed in ASM from volunteers with and without asthma. Data
obtained ex-vivo showed that FBLN-1 protein levels and FBLN-1C
mRNA levels in ASM cells derived from asthmatics were higher
than those derived from non-asthmatics. Our observation that
TGFb decreased FBLN-1D mRNA expression (figure 2D) was
consistent with the findings of Laprise et al., who reported reduced
FBLN-1D mRNA expression in lysates from asthma derived
bronchial biopsies compared with those derived from non-
asthmatics [15]. The differential regulation of the specific isoforms
of FBLN-1 indicates that they may have opposing or compensa-
tory effects [33]. Given our findings of increased FBLN-1 protein
in asthmatic ASM cells and the lack of information about FBLN-
1C we chose to elucidate the role of FBLN-1C in this study.
We demonstrated that TGFb not only increased FBLN-1 in
asthma derived ASM cells, but also enhanced its deposition in the
asthmatic ECM. The architecture of the asthmatic airway often
undergoes prominent and permanent structural changes, including
alterations of the molecular composition of the ECM. In
particular, ECM protein deposition is increased in the lamina
reticularis [34], resulting in basement membrane thickening [35].
Given that TGFb levels may alter the ECM assembly process, it is
likely that the raised TGFb levels in the asthmatic airway may
contribute to an increase in the ECM thereby augmenting the
effects of airway remodeling.
Lung injury resulting from inflammation contributes to the
remodeling process [36]. It is hypothesized that smooth muscle
Figure 8. FBLN-1C AO inhibits FBLN-1 but not FN deposition by asthmatic ASM cells. ASM cells grown on glass coverslips in the presence
of either a FBLN-1 specific AO or a scrambled AO were stimulated with TGFb and FBLN-1 and FN were detected using antibodies labeled with
different fluorochromes. Images are representative of results from 4 ASM cell lines.
doi:10.1371/journal.pone.0013360.g008
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precursor cells from beyond the borders of the muscle or
proliferating cells within the muscle bundles are recruited to the
site of injury. In the present study, we examined the proliferative,
migratory and wound closure properties of ASM cells derived
from those with and without asthma. Notably, a recent ex vivo and
in-vitro studies have indicated that proliferation is increased in
asthma derived cells [3,4,22]. Our data support the current
literature and, in addition, provide the first evidence that
migration and wound closure are increased in asthmatic ASM
cells. Wound healing involves synchronized events of cell
proliferation, migration and differentiation [37]. Cell migration
is a complex phenomenon and the wound assay has advantages
over transwell or boyden chamber techniques which allow
chemotaxis of cells freed from their native matrix to be
investigated. In contrast, the wound assay allows for cell
movement to be assessed in the absence of disruption of cell-cell
or cell-ECM interactions and thus allows migration of a connected
population of cells to be measured. If the increased cross-sectional
area observed in airway remodeling in asthma is, at least in part,
due to migration of the smooth muscle cells towards the lumen
then it is likely that these cells are interacting with the surrounding
environment and modulated by the ECM. In this study we showed
cell proliferation and migration are abnormal in asthmatic ASM
cells, suggesting that these events may contribute to aberrant
repair processes in the asthmatic airway.
We confirmed that the ECM is another important factor in
determining the properties of the ASM cells. Wound repair, cell
proliferation and migration were all enhanced when either the
ASM or the ECM was derived from asthmatic volunteers, a
finding which is consistent with the hypothesis of previous studies
[8,34,38]. We assessed the impact of FBLN-1 on cell proliferation,
migration and wound repair.
Decreasing the level of FBLN-1C in the asthmatic ASM cell
derived ECM components abrogated increased cell proliferation
and wound repair, but not migration. We did not examine the
effect of knocking out FBLN-1C in the non-asthmatic ECM as we
were unable to induce FBLN-1 in this matrix with TGFb. This
indicates that the increased FBLN-1C levels in asthmatics
contribute to wound repair and remodeling by increasing cell
Figure 9. FBLN-1C promotes wound healing in asthmatic ASM
cells. The degree of closure, measured over time, of a 1cm wound
induced in non-asthmatic (n = 6–7) or asthmatic (n = 6–7) ASM cells
reseeded on an ECM deposited by an asthmatic ASM cell line in the
presence (dark red line (asthmatic) and dark blue line (non-asthmatic))
or absence (resulting from treatment with a FBLN-1C AO, light red line
(asthmatic) and light blue line (non-asthmatic)) of FBLN-1C. Wound
healing rates were measured basally (0.1% BSA) (A) or following
stimulation with TGFb (B). Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g009
Figure 10. FBLN-1C promotes proliferation of ASM cells. FBLN-
1C in the ECM deposited by an asthmatic ASM cell line was inhibited by
a FBLN-1C specific AO. ASM cells from non-asthmatic (n = 4) or
asthmatic (n = 4–5) volunteers were reseeded on the ECM and the
effect on cell proliferation in response to 5% FBS was determined. Data
are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g010
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proliferation rather than cellular migration. We did not observe
any additive effect on wound repair or proliferation when FBLN-
1C in both ASM and ECM was downregulated (data not shown),
which suggests that decreasing FBLN-1C in either component is
adequate to inhibit these cellular processes.
Silencing FBLN-1C did not alter ASM cell migration in our
study. This is in contrast with the findings of Qing et al., who
reported that a fibrosarcoma-derived cell line transfected with
FBLN-1D had decreased invasive potential [39]. However, these
authors studied FBLN-1D, whilst in our studies, we designed our
AO to target FBLN-1C, which appears to have different properties
to the other FBLN-1 isoforms [33]. In addition, a recent study
showed FBLN-1C negatively regulated proliferation in human
osteoblasts, indicating that the actions of the FBLN-1 isoforms are
likely to be cell type specific [40]. Thus although FBLN-1 has been
reported to decrease [41] and increase [32] wound repair in other
organs, our study provides compelling evidence for a role for
FBLN-1, specifically the 1C isoform, in increasing wound repair
and remodeling in the airways.
AHR is a hallmark feature of asthma that has been linked to the
pathological events associated with remodeling of the airway wall.
TGFb has also been linked to the mechanism underpinning AHR
in asthma. In particular, TGFb administration to the airways in
mice induces peribronchial fibrosis that results in the development
of AHR [42]. TGFb induced AHR in the murine model we
employed in our study. When these animals were treated with
AOs targeting FBLN-1, TGFb induced AHR was inhibited
demonstrating a critical role for FBLN-1 in the mechanism of
TGFb induced AHR. Notably, this is, to our knowledge, the first
report demonstrating that inhibition of a matrix protein reduces
AHR, thereby providing direct evidence for the role of the ECM
in regulating AHR in this model. This suggests that FBLN-1 may
Figure 11. FBLN-1C does not alter migration of ASM cells.
Migratory rates of non-asthmatic (white, n = 4–5) and asthmatic (black,
n = 4–6) ASM reseeded on an ECM deposited by an asthmatic ASM cell
line in the absence (A) or presence (B) of a chemoattractant (5% FBS). (C)
ASM cells from non-asthmatic (n = 4) or asthmatic (n= 4–5) volunteers
were reseeded onto an asthmatic ECM in which FBLN-1C was inhibited by
a FBLN-1C specific AO and the effect on cell migration in response to 5%
FBS was determined. Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0013360.g011
Figure 12. FBLN-1 contributes to the airway resistance of mice
treated with TGFb. Adult BALB/c mice (6–8 weeks old) were treated
twice (day 0 & 1) with either recombinant human TGFb or PBS. Seven
mice were treated with the FBLN-1 AO daily for the first 7 days, and
then 3 times weekly for the following three weeks. Specific airway
resistance to methacholine was measured using whole body plethys-
mography. Data are expressed as percentage change compared with
PBS and shown as mean 6 SEM. n = 7 for all groups except saline/saline
for which n= 6. TGFb/Saline is significantly greater than saline/saline
(denoted by *) at 5, 10 and 20 mg/ml methacholine, p,0.05, p,0.01,
p,0.001 respectively. TGFb/FBLN-1 AO is significantly reduced (denot-
ed by #) compared with TGFb/Saline at 20 mg/ml methacholine
p,0.05.
doi:10.1371/journal.pone.0013360.g012
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play a pivotal role in the processes that drive airway wall lesions in
asthma that lead to enhanced airways reactivity. The regulated
expression of FBLN-1 downstream of inflammation and its
regulation of the remodeling/AHR axis identify the therapeutic
potential of targeting this glycoprotein.
We were afforded the opportunity to study FBLN-1 levels in
BAL fluid and serum from asthmatic volunteers both before and
after administration of corticosteroids, and showed that treatment
had no effect on FBLN-1. In our study population we did not
observe a correlation between the level of FBLN-1 detected and
the FEV1/FVC ratio. However, the range of asthma severity in
our study may have been too narrow to enable the demonstration
of such a relationship. If, as our results in the present study suggest,
FBLN-1 is implicated in airway remodeling, then the lack of effect
of corticosteroids on levels of FBLN-1 in-vivo highlights the need
for treatments that target the structural changes which contribute
to airway remodeling in asthma. The findings in our cell and
animal based models indicate that FBLN-1 warrants further
investigation as a novel target for therapeutic intervention to
prevent airway remodeling.
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